Detre K M, Levy R I, Kelsey S F, Epstein S E, Brensike J F, Passamani E R, Richardson J M, Loh I K, Stone N J, Aldrich R F
Am Heart J. 1985 Nov;110(5):1123-7. doi: 10.1016/0002-8703(85)90227-3.
In a secondary prevention trial conducted by the National Heart, Lung, and Blood Institute, the effect of lipid lowering by drug intervention on the progression of existing coronary artery disease (CAD) was evaluated in type II hyperlipidemic patients. This first randomized, secondary prevention trial compared the effect of cholestyramine and diet with that of placebo and diet in 143 patients over a 5-year period. End points evaluated were progression or regression of CAD, as demonstrated by angiographic changes compared with baseline angiograms. The cholestyramine-treated group demonstrated a significant reduction in total cholesterol and in low-density lipoprotein cholesterol (LDL) levels as compared with placebo, and an 8% increase in high-density lipoprotein cholesterol (HDL). A statistically significant result supporting the use of cholestyramine treatment was found in one category of CAD progression.
在美国国立心肺血液研究所开展的一项二级预防试验中，研究人员评估了药物干预降低血脂对II型高脂血症患者现有冠状动脉疾病（CAD）进展的影响。这项首个随机二级预防试验在143名患者中比较了考来烯胺与饮食结合疗法和安慰剂与饮食结合疗法在5年期间的效果。评估的终点是CAD的进展或逆转，通过与基线血管造影相比的血管造影变化来证明。与安慰剂相比，考来烯胺治疗组的总胆固醇和低密度脂蛋白胆固醇（LDL）水平显著降低，高密度脂蛋白胆固醇（HDL）增加了8%。在CAD进展的一个类别中发现了支持使用考来烯胺治疗的统计学显著结果。
